ST2 provides new
insight on cardiovascular disease progression—relevant disease state
information not reflected by other biomarkers and clinical
Multiple published studies by leading investigators from
around the world have demonstrated that ST2 is a powerful prognostic cardiac
biomarker available, and when used in conjunction with other clinical
parameters, which may help physicians make better clinical decisions.
ST2 is most useful in determining the patient's likely
prognosis, regardless of their symptom status. Furthermore, ST2 enhances
prognosis when used in conjunction with natriuretic peptide markers.